Introduction

Thank you for your interest in taking part in this online survey of patients and survivors. This survey will be used as part of Lymphoma Canada's submission to the Canadian Drug Association (www.cda-amc.ca), and the Quebec equivalent INESSS (Institut national d'excellence en santé et services sociaux). These agencies assess drugs for clinical and cost-effectiveness compared to other treatments that are currently available and makes recommendations to provinces and territories to guide their drug funding decisions.

The purpose of this survey is to help develop a complete and thorough submission to help governments understand the value of new cancer drugs to patients. The drug that will soon be reviewed by CDA/INESSS is for Acalabrutinib in combination with bendamustine and rituximab. Acalabrutinib, also known as Calquence, is an oral Bruton’s tyrosine kinase (BTK) inhibitor. This treatment, in combination with bendamustine and rituximab is being submitted for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL).

If you have MCL and have received treatment with Acalabrutinib, your feedback is extremely important and may help improve access to this new drug for patients in Canada. The greater the response, the better our data will be!

YOU DO NOT HAVE TO BE A CANADIAN RESIDENT TO RESPOND TO THIS SURVEY.

WE APPRECIATE INPUT FROM ALL MCL PATIENTS.
You can still participate if you have not been treated with Acalabrutinib.
If you have any questions, concerns, or technical difficulties while completing this survey, please contact info@lymphoma.ca

Privacy Policy: To ensure patient privacy and confidentiality, individual responses will not be identifiable. It is important to note that selected quotations may be used for the final submission to government agencies without reference to patient name or any other information that could lead to identifying the patient.

Question Title

* 1. Have you been diagnosed with Mantle Cell Lymphoma (MCL) ?

T